Boston Family Office LLC Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Boston Family Office LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 134,939 shares of the medical research company’s stock after selling 1,019 shares during the period. IQVIA accounts for about 1.8% of Boston Family Office LLC’s holdings, making the stock its 12th largest holding. Boston Family Office LLC owned 0.07% of IQVIA worth $26,517,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Geode Capital Management LLC increased its holdings in shares of IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after acquiring an additional 77,981 shares in the last quarter. HighPoint Advisor Group LLC increased its stake in IQVIA by 22.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,133 shares of the medical research company’s stock valued at $428,000 after purchasing an additional 395 shares in the last quarter. Franklin Resources Inc. raised its holdings in IQVIA by 4.7% in the fourth quarter. Franklin Resources Inc. now owns 525,489 shares of the medical research company’s stock worth $103,264,000 after buying an additional 23,682 shares during the last quarter. B. Metzler seel. Sohn & Co. AG lifted its stake in shares of IQVIA by 0.4% in the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 625,712 shares of the medical research company’s stock worth $123,029,000 after buying an additional 2,496 shares in the last quarter. Finally, Cannell & Spears LLC grew its holdings in shares of IQVIA by 107.6% during the fourth quarter. Cannell & Spears LLC now owns 39,888 shares of the medical research company’s stock valued at $7,838,000 after buying an additional 20,678 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several recent analyst reports. Robert W. Baird cut their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Finally, Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Down 0.6 %

Shares of IQV stock opened at $176.28 on Tuesday. The stock has a fifty day simple moving average of $192.73 and a two-hundred day simple moving average of $205.61. IQVIA Holdings Inc. has a 52-week low of $169.37 and a 52-week high of $253.84. The firm has a market capitalization of $31.08 billion, a PE ratio of 23.50, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.